

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Rubinson 1



Section 1. Identif	ying Information				
1. Given Name (First Name) Douglas	2. Surna Rubinso	ame (Last Name) on		3. Date 05-June-2021	I
4. Are you the corresponding	g author? Yes	√ No	Corresponding Author	or's Name	
5. Manuscript Title Durable Clinical Benefit from PARP Inhibition in a Platinum-Sensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlier Progression on Placebo Treatment on the POLO Trial 6. Manuscript Identifying Number (if you know it) JGO-21-197					itient After Earlier
Section 2. The Wo	ork Under Considera	ation for Publi	cation		
Did you or your institution at any aspect of the submitted vistatistical analysis, etc.)? Are there any relevant con	work (including but not li				
Section 3. Relevan	nt financial activitie	s outside the	submitted work.		
Place a check in the appro of compensation) with ent clicking the "Add +" box. Y Are there any relevant con If yes, please fill out the ap	rities as described in the You should report relations of interest?	e instructions. U onships that we Yes	se one line for each er	ntity; add as many lir	nes as you need by
Name of Entity	Grant	Personal No	n-Financial Other?	Comments	
Boston Scientific		✓			
Section 4. Intellec	tual Property Pat	ents & Copyri	ghts		
Do you have any patents,	whether planned, pend	ding or issued, b	roadly relevant to the	work? Yes	/ No

Rubinson 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Rubinson reports personal fees from Boston Scientific, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Rubinson 3

ICMJE DISCLOSURE FORM

Date: August 11, 2021
Your Name: Brian Wolpin
Manuscript Title: JGO-21-197-R1
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planni	Specifications/Comments (e.g., if payments were made to you or to your institution) ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past 36 mor	nths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Eli Lilly and Company Celgene, Inc	Research funding Research funding
3	Royalties or licenses	XNone	
4	Consulting fees	BioLineRx Grail Celgene, Inc	Consultant Consultant Consultant
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	

	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
committee or advocacy			
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

P	lease summarize	the above	conflict of	interest i	in th	e fol	lowing I	DOX
---	-----------------	-----------	-------------	------------	-------	-------	----------	-----

BMW receives grant support from Celgene and Eli Lilly, and has consulted for BioLineRx, Celgene and GRAIL.	

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information
1. Given Name (First Name) 2 Surname (Last Name) Warsofsky 4 Are you the corresponding author? Yes Tho
4 Are you the corresponding author? Yes No
 Manuscript Title Durable Clinical Benefit from PARP Inhibition in a Platinum-Sensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlier Progression on Placebo Treatment on the POLO Trial Manuscript Identifying Number (if you know it) JGO-21-197
Section 2. The Work Under Consideration for Publication
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes Yes
Section 3. Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No
Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work?



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

1. Given Name (First Name) David	Surname (Last Nan Ryan	ne) 3. Date 20-August-2021
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name
5. Manuscript Title Durable Clinical Benefit from PARP Inh Progression on Placebo Treatment on 6. Manuscript Identifying Number (if you l JGO-21-197	the POLO Trial	ensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlier
Section 2. The Work Under 0	Consideration for Pu	ublication
any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not limited to gran rest?	from a third party (government, commercial, private foundation, etc.) for its, data monitoring board, study design, manuscript preparation, No
If yes, please fill out the appropriate in Excess rows can be removed by pressi	•	u have more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support? Comments
Astrazeneca	✓	Clinical Trial Funding
Place a check in the appropriate boxes of compensation) with entities as desc	in the table to indicate ribed in the instruction eport relationships that rest?	the submitted work. e whether you have financial relationships (regardless of amount as. Use one line for each entity; add as many lines as you need by t were present during the 36 months prior to publication. No
Name of Entity	Grant? Personal Fees?	Non-Financial Support? Comments
SU2C	✓	Pancreatic Cancer Trial
EXAS/Thrive		Stock compensation
МРМ		Consulting fees and stock compensation



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Boeringer Ingelheim			Consulting Fees	
UpToDate			Authorship Fee	
Continue				
Section 4. Intellectual Pr	roperty Patents & Cop	oyrights		
Do you have any patents, whether	r planned, pending or issue	ed, broadly relevant	t to the work? Yes V No	
Section 5. Relationships	s not covered above			
Are there other relationships or acceptance of the following relationship what you was a few of the following relationship with the time of manuscript acceptance on occasion, journals may ask automatically acceptance of the following relationships or acceptance or acceptance of the following relationships or acceptance or acceptance of the following relationships or acceptance o	wrote in the submitted works os/conditions/circumstance ons/circumstances that pre unce, journals will ask autho	rk? s are present (explaces esent a potential co ors to confirm and, i	ain below): onflict of interest if necessary, update their disclosu	
Section 6. Disclosure Sta	atement			
Based on the above disclosures, the below.	nis form will automatically લ્	generate a disclosu	ire statement, which will appear in	the box
			nts from SU2C, personal fees from anal fees from UpToDate, outside	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

📕 Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Informa	ation		
1. Given Name (First Name)	2. Surname (Last Name)	3. Dat	te 0/7/2021
4. Are you the corresponding author?	Yes No		
5. Manuscript Title Durable Clinical Benefit from PARP Inhib Progression on Placebo Treatment on th 6. Manuscript Identifying Number (if you kno	e POLO Trial	RCA2-Mutated Pancreatic C	ancer Patient After Earlier
JGO-21-197			
Section 2. The Work Under Co	nsideration for Publicatio	n	
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest	but not limited to grants, data mo	d party (government, commerc nitoring board, study design, m	ial, private foundation, etc.) for nanuscript preparation,
Section 3. Polyant financial a	activities outside the subn	itted work	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repare there any relevant conflicts of interests.	n the table to indicate whether bed in the instructions. Use on bort relationships that were pre	you have financial relations e line for each entity; add as	many lines as you need by
Section 4. Intellectual Proper	ty Patents & Copyrights		
Do you have any patents, whether plann	ned, pending or issued, broadly	relevant to the work?	Yes No



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1.	Identifying Inform	ation					
1. Given Name (Fii Osama	rst Name)	2. Surnar Rahma	ne (Last Nar	ne)		3. Date 26-September-2021	
4. Are you the cor	responding author?	Yes	✓ No	Correspond	ding Autho	or's Name	
Progression on P	Benefit from PARP Inhik lacebo Treatment on th	ne POLO T		ensitive, BRCA2-I	Mutated I	Pancreatic Cancer Patient After Earlie	r
6. Manuscript Ider JGO-21-197	ntifying Number (if you kn	ow it)					
Section 2.							
Section 2.	The Work Under Co	nsiderat	tion for P	ublication			
	ubmitted work (including					ent, commercial, private foundation, etc.) udy design, manuscript preparation,	for
Are there any rele	evant conflicts of intere	st? ✓	res 🗌	No			
	out the appropriate info oe removed by pressing			u have more than	one enti	ity press the "ADD" button to add a ro	ow.
Name of Institut	ion/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Astrazeneca			√			Employment	
Section 3.	Relevant financial	activities	outside	the submitted	work.		
of compensation) with entities as descri	oed in the	instruction	ns. Use one line fo	or each er	cial relationships (regardless of amountity; add as many lines as you need be a months prior to publication.	
•	evant conflicts of intere			No			
If yes, please fill o	out the appropriate info	rmation b	elow.				
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Merck		✓	✓			Research support and educational grants. Consulting fees	
Celgene			✓				
Five Prime			✓				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
GSK		√						
Bayer		✓						
Roche/Genentech		√						
Puretech		✓						
Imvac		✓						
Sobi		✓						
Section 4. Intellectual Prop								
Do you have any patents, whether plants of the second seco	nformation k	elow. If yo	•			ow.		
Patent? Pend	ding? Issue	ed? Licens	ed?Royalties?	License	e? Comments			
Methods of using pembrolizumab and trebananib	✓							
Section 5. Relationships no	ot covered	above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/co								
At the time of manuscript acceptance On occasion, journals may ask author						nts.		

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rahma reports personal fees from Astrazeneca, during the conduct of the study; grants and personal fees from Merck, personal fees from Celgene, personal fees from Five Prime, personal fees from GSK, personal fees from Bayer, personal fees from Roche/Genentech, personal fees from Puretech, personal fees from Imvac, personal fees from Sobi, outside the submitted work; In addition, Dr. Rahma has a patent Methods of using pembrolizumab and trebananib pending.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Singh 1



Section 1.	Identifying Inform	nation						
1. Given Name (Fi Harshabad	rst Name)	2. Surname (Last Name) Singh	3. Date 07-June-2021					
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name James Cleary					
5. Manuscript Title Durable Clinical Benefit from PARP Inhibition in a Platinum-Sensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlie Progression on Placebo Treatment on the POLO Trial 6. Manuscript Identifying Number (if you know it) JGO-21-197								
Section 2.	The Work Under Co	onsideration for Public	ration					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No								
Section 3.	Relevant financial	activities outside the s	ubmitted work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No								
Section 4.	Intellectual Proper	ty Patents & Copyric	jhts					
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes 🗸 No					

Singh 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Singh has no	thing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Singh 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Yurgelun 1



Section 1. Identifying Inform	ation		
Given Name (First Name) Matthew	2. Surname (Last Name) Yurgelun		3. Date 08-June-2021
4. Are you the corresponding author?	Yes ✓ No	Corresponding Auth James Cleary, MD	or's Name
5. Manuscript Title Durable Clinical Benefit from PARP Inhib Progression on Placebo Treatment on th 6. Manuscript Identifying Number (if you known) JGO-21-197	ne POLO Trial	ive, BRCA2-Mutated	Pancreatic Cancer Patient After Earlier
Section 2. The Work Under Co			
The Work Under Co	nsideration for Public	cation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?			ent, commercial, private foundation, etc.) for tudy design, manuscript preparation,
Are there any relevant conflicts of intere	st?		
Section 3. Relevant financial a	activities outside the s	submitted work.	
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere	oed in the instructions. Us ort relationships that we	se one line for each e	ntity; add as many lines as you need by
If yes, please fill out the appropriate info	rmation below.		
Name of Entity	Grant? Personal Fees? S	n-Financial other	Comments
Janssen Pharmaceuticals	✓		Research funding and consulting/ scientific advisory board participation
UpToDate			Fees for peer review services
Section 4. Intellectual Proper	ty Patents & Copyric	ghts	
Do you have any patents, whether planr	ned, pending or issued, br	oadly relevant to the	ework? ☐ Yes 🗸 No

Yurgelun 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Yurgelun reports grants and personal fees from Janssen Pharmaceuticals, personal fees from UpToDate, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Yurgelun 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Shapiro 1



Section 1. Identifying Inform	ation								
Given Name (First Name) Geoffrey	2. Surname (I Shapiro	_ast Name)			3. Date 08-June-2021				
4. Are you the corresponding author?	Yes	No	Correspond James M. C	•	or's Name				
5. Manuscript Title Durable Clinical Benefit from PARP Inhibition in a Platinum-Sensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlier Progression on Placebo Treatment on the POLO Trial 6. Manuscript Identifying Number (if you know it) JGO-21-197									
Section 2. The Work Under Co		(D. I.	l' • · - · -						
Did you or your institution at any time receiven any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited								
Section 3. Relevant financial a	activities ou	tside the	submitted	work.					
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should rep	oed in the inst	tructions.	Use one line fo	r each er	ntity; add as many lines as you need by				
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		No							
Name of Entity	Grant? Per	rsonal Ne	on-Financial Support	Other?	Comments				
Eli Lilly	✓				Sponsored Research Agreement				
Merck KGaA/EMD Serono	✓	✓			Sponsored Research Agreement and Scientific Advisory Board				
Merck & Co.		✓			Sponsored Research Agreement				
Sierra Oncology	✓	✓			Sponsored Research Agreement and Scientific Advisory Board				
Pfizer		✓			Scientific Advisory Board				
G1 Therapeutics		✓			Scientific Advisory Board				
Bicycle Therapeutics		1			Scientific Advisory Board				

Shapiro 2



Patent?

ICMJE Form for Disclosure of Potential Conflicts of Interest

Name of Entity	Grant •	Fees?	Support?	Other •	Comments			
Roche		✓			Scientific Advisory Board			
Fusion Pharmaceuticals		✓			Scientific Advisory Board			
Cybrexa Therapeutics		✓			Scientific Advisory Board			
Astex		✓			Scientific Advisory Board			
Almac		✓			Scientific Advisory Board			
lpsen		✓			Scientific Advisory Board			
Bayer		✓			Scientific Advisory Board			
Angiex		✓			Scientific Advisory Board			
Daiichi Sankyo		✓			Scientific Advisory Board			
Seattle Genetics		✓			Scientific Advisory Board			
Boehringer Ingelheim		✓			Scientific Advisory Board			
ImmunoMet		✓			Scientific Advisory Board			
Asana		✓			Scientific Advisory Board			
Artios		✓			Scientific Advisory Board			
Atrin		✓			Scientific Advisory Board			
Concarlo Holdings		✓			Scientific Advisory Board			
Syros		✓			Scientific Advisory Board			
Zentalis		✓			Scientific Advisory Board			
CytomX Therapeutics		✓			Scientific Advisory Board			
Blueprint Medicines		✓			Scientific Advisory Board			
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row.								

Shapiro 3

Licensee?

Comments

Pending? Issued? Licensed? Royalties?



 $| \mathbf{v} |$ No other relationships/conditions/circumstances that present a potential conflict of interest

Patent?	Pending?	Issued?	Licensed?	Royalties?	Licensee?	Comments
Dosage regimen for sapacitabine and seliciclib		✓			Cyclacel Pharmaceuticals and Geoffrey Shapiro	
Compositions and Methods for Predicting Response and Resistance to CDK4/6 inhibition					Liam Cornell and Geoffrey Shapiro	
Section 5. Relationshi	ps not cove	ered abo	ove			
Are there other relationships or potentially influencing, what yo			•	eive to have	influenced, or tha	at give the appearance of
Yes, the following relationsh	ips/conditio	ns/circum	nstances are	e present (ex	plain below):	

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosur

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Shapiro reports grants from Eli Lilly, grants and personal fees from Merck KGaA/EMD Serono, personal fees from Merck & Co., grants and personal fees from Sierra Oncology, personal fees from Pfizer, personal fees from G1 Therapeutics, personal fees from Bicycle Therapeutics, personal fees from Roche, personal fees from Fusion Pharmaceuticals, personal fees from Cybrexa Therapeutics, personal fees from Astex, personal fees from Almac, personal fees from Ipsen, personal fees from Bayer, personal fees from Angiex, personal fees from Daiichi Sankyo, personal fees from Seattle Genetics, personal fees from Boehringer Ingelheim, personal fees from ImmunoMet, personal fees from Asana, personal fees from Artios, personal fees from Atrin, personal fees from Concarlo Holdings, personal fees from Syros, personal fees from Zentalis, personal fees from CytomX Therapeutics, personal fees from Blueprint Medicines, outside the submitted work; In addition, Dr. Shapiro has a patent Dosage regimen for sapacitabine and seliciclib issued to Cyclacel Pharmaceuticals and Geoffrey Shapiro, and a patent Compositions and Methods for Predicting Response and Resistance to CDK4/6 inhibition pending to Liam Cornell and Geoffrey Shapiro.

Shapiro 4



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Shapiro 5



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Lisans and The material has been lisans and to an enti-

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inforr	mation							
1. Given Name (F Andrew	irst Name)	2. Surnar Aguirre	me (Last Nar	me)		3. Date 09-June-2021			
4. Are you the co	rresponding author?	Yes	✓ No	-	Corresponding Author's Name James Cleary				
Progression on I		the POLO T		Sensitive, BRCA2-	Mutated F	Pancreatic Cancer Patient After Earlier			
Section 2.	The Work Under (Considera	tion for P	ublication					
any aspect of the statistical analysis	submitted work (includin	g but not lin	nited to grar			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,			
If yes, please fill	out the appropriate in	formation b	elow. If yo		one enti	ty press the "ADD" button to add a row.			
Excess rows can	be removed by pressir			Non Etalon del					
Name of Institu	tion/Company	Grant?	Personal Fees?	Non-Financial Support?	Other	Comments			
National Cancer Inst	itute	√							
ustgarten Foundati	on	√							
Pancreatic Cancer Ad	ction Network	√							
Doris Duke Charitabl	le Foundation	✓							
Dana-Farber Cancer Pancreatic Cancer Re	Institute Hale Center for esearch	✓							
Soction 2									
Section 3.	Relevant financia	activities	outside '	the submitted	work.				
of compensation clicking the "Add	n) with entities as desc d +" box. You should re	ribed in the port relatio	instruction	ns. Use one line fo It were present d	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication .			
•	levant conflicts of inter out the appropriate in			No					



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Mirati Therapeutics	✓				Sponsored Research Agreement
Merck		√			Consulting
Arrakis Therapeutics		✓			Consulting
Oncorus		✓			Consulting
Deerfield, Inc	✓				
Novo Ventures	✓				
Syros Pharmaceuticals	✓	✓			Sponsored Research, Consulting
Section 5. Relationships not of	·	-	,		work?
Are there other relationships or activities			perceive to have i	influence	d, or that give the appearance of
potentially influencing, what you wrote	in the sub	mitted wo	rk?		
Yes, the following relationships/cond	ditions/cir	cumstance	s are present (exp	plain belo	ow):
✓ No other relationships/conditions/cii	rcumstan	ces that pre	esent a potential	conflict o	finterest
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form below.		omatically (generate a disclos	sure state	ement, which will appear in the box

Action Network, grants from Doris Duke Charitable Foundation, grants from Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer Research, during the conduct of the study; grants from Mirati Therapeutics, personal fees from Merck, personal fees from Arrakis Therapeutics, personal fees from Oncorus, grants from Deerfield, Inc, grants from Novo Ventures, grants and personal fees from Syros Pharmaceuticals, outside the submitted work; .



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Information	ation								
1. Given Name (First Name) Alan	2. Surnar D'Andre	me (Last Nar a	ne)		3. Date 15-June-2021				
4. Are you the corresponding author?	Yes	✓ No	Correspond	ding Autho	or's Name				
5. Manuscript Title Durable Clinical Benefit from PARP Inhibition in a Platinum-Sensitive, BRCA2-Mutated Pancreatic Cancer Patient After Earlier Progression on Placebo Treatment on the POLO Trial 6. Manuscript Identifying Number (if you know it) JGO-21-197									
Section 2. The Work Under Co	nsidera	tion for P	ublication						
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest	but not lim	nited to gran		_	•	c.) for			
Section 3. Relevant financial a	ctivities	outside	the submitted t	work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest?									
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Bayer AG		√			Consultant				
Cedilla Therapeutics		/		✓	Founder, Scientific Advisory Board Member, and Stockholder				
Cyteir Therapeutics		✓		✓	Scientific Advisory Board Member, and Stockholder				
pizyme, Inc.		✓			Consultant				
GalaxoSmithKline		✓			Consultant				
deaya, Inc.		✓		✓	Scientific Advisory Board Member, and Stockholder				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Impact Therapeutics		✓			Consultant		
LAV Global Management		\checkmark			Consultant		
L.E.K. Consulting		✓			Consultant		
Lilly Oncology	✓	✓			Consultant, Sponsored Research Agreement		
Merck KGAa/EMD Serono	✓	✓			Consultant, Sponsored Research Agreement		
Novartis Bioventures		✓			Consultant		
Novo Ventures		✓			Consultant		
Pfizer		✓			Consultant		
Tango Therapeutics		✓			Consultant		
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							
Section 5. Relationships not covered above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships							



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. D'Andrea reports personal fees from Bayer AG, personal fees and other from Cedilla Therapeutics, personal fees and other from Cyteir Therapeutics, personal fees from Epizyme, Inc., personal fees from GalaxoSmithKline, personal fees and other from Ideaya, Inc., personal fees from Impact Therapeutics, personal fees from LAV Global Management, personal fees from L.E.K. Consulting, grants and personal fees from Lilly Oncology, grants and personal fees from Merck KGAa/EMD Serono, personal fees from Novartis Bioventures, personal fees from Novo Ventures, personal fees from Pfizer, personal fees from Tango Therapeutics, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

koyaities: Funds are coming in to you or your institution due to your patent



Continue 1					
Section 1. Identifying Information	ation				
1. Given Name (First Name) James	2. Surname (Last Nam Cleary	3. Date 08-June-2021			
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title Durable Clinical Benefit from PARP Inhib Progression on Placebo Treatment on th 6. Manuscript Identifying Number (if you known JGO-21-197	e POLO Trial	ensitive, BRCA2-N	Mutated Pancrea	tic Cancer Patient After B	Earlier
Section 2. The Work Under Co	nsideration for Pu	blication			
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interests.	but not limited to grant	s, data monitoring			
Section 3. Relevant financial a	ctivities outside t	he submitted v	work.		
Place a check in the appropriate boxes ir of compensation) with entities as descrik clicking the "Add +" box. You should rep Are there any relevant conflicts of interes If yes, please fill out the appropriate info	oed in the instruction ort relationships that st? Yes	s. Use one line fo	or each entity; ad	d as many lines as you n	eed by
Name of Entity	Grant? Personal Fees?	Non-Financial Support	Other? Com	ments	
AZD		√			
Abbvie	✓		To his ir	nstitution	
Merus	✓		To his ir	nstitution	
Roche	✓		To his ir	nstitution	
BMS	✓		To his ir	nstitution	
Merck	✓				
Esperas Pharma		✓			
Tesaro					



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
BMS		✓						
Syros					Honorarium for advisory board			
Section 4. Intellectual Property Patents & Copyrights								
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes V No			
Section 5. Relationships not c	overed	above						
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/cir No other relationships/conditions/cir At the time of manuscript acceptance, journals may ask authors to	n the sub litions/cir cumstan urnals wi	omitted wo cumstance ces that pro	rk? es are present (expessent a potential of ers to confirm and	olain belc conflict o	ow): f interest sary, update their disclosure staten	nents.		
Section 6. Disclosure Statemen	nt							
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box	ζ		
Dr. Cleary reports non-financial support BMS, grants from Merck, non-financial su Syros, outside the submitted work; .						m		



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.